Keros Therapeutics has abandoned a phase 2 trial of its drug candidate for pulmonary arterial hypertension (PAH), cibotacept, after seeing evidence of potentially serious cardiovascular side effects.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2025,